Sobi Repurchases Shares to Secure Incentive Program Commitments

Swedish Orphan Biovitrum AB (Sobi) has announced that its Board of Directors has decided to exercise its authorization to repurchase shares. The decision concerns all issued class C shares and is aimed at securing the company's commitments under a previously approved employee incentive program.

The repurchase will be conducted between July 16 and November 6, 2026. The company will acquire the class C shares at 100 percent of their quotient value, equivalent to approximately SEK 0.55 per share. This action is a follow-through from the Annual General Meeting's resolution to facilitate the incentive program.

Following the repurchase, the acquired class C shares are intended to be converted into common shares. This conversion will increase Sobi's holding of own common shares from the current 10,067,297 to 10,290,974. The move is part of Sobi's financial management of its incentive schemes.

Sobi is a global biopharmaceutical company dedicated to rare diseases, with revenues of SEK 28 billion in 2025. The company operates internationally and its shares are listed on Nasdaq Stockholm.